MicroRNA (miRNA) sponges allow the selective blockade of a complete family of associated miRNAs, which induce post-transcriptional gene silencing in their target through binding to 3′UTR mRNA. miRNA-365 and miRNA-145 are downregulated in colorectal cancer (CRC) but not in healthy tissues. Based on this, we constructed two vectors by inserting miRNA sponges (one for miRNA-365 and other for miRNA-145), and used enhanced green fluorescent protein (EGFP) as a 3′UTR reporter gene to analyze the ability of each sponge to catch its respective miRNA. Quantitative polymerase chain reaction (qPCR) results corroborated that the expression levels of both miRNAs were lower in CRC cell lines than in normal colon cell lines. Flow cytometry analysis revealed a decrease of the EGFP expression levels in the cell lines transfected with both sponges, being higher on the normal cell line while CRC cell lines presented a minimal decline. Also, this decrease was inversely proportional to the levels of expression of both miRNAs obtained by qPCR. These results were corroborated by fluorescence microscopy, showing a similar decrease in fluorescence. We propose a new vector system to carry in a specific way the expression of genes to CRC cells without affecting healthy cells, preventing damage to healthy tissues.
Get full access to this article
View all access options for this article.
References
1.
BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68:394–424.
2.
SiegelRL, MillerKD and JemalA. (2018). Cancer statistics, 2018. CA Cancer J Clin, 68:7–30.
3.
HernandezR, Sanchez-JimenezE, MelguizoC, PradosJ and RamaAR. (2018). Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives. BMB Rep, 51:563–571.
4.
AcunzoM and Croce.CM (2015). MicroRNA in cancer and cachexia—a mini-review. J Infect Dis 212 (Suppl. 1):S74–S77.
5.
KimY, EomS, ParkD, KimH and Jeoung.D (2015). The hyaluronic acid-HDAC3-miRNA network in allergic inflammation. Front Immunol, 6:210.
6.
PangHL, ZhaoQQ, MaY, SongYL, MinJ, LuJR, LiH and Zhao.DQ (2019). Long noncoding RNA H19 participates in the regulation of adipose-derived stem cells cartilage differentiation. Stem Cells Int, 2019:2139814.
SugitoN, TaniguchiK, KuranagaY, OhishiM, SogaT, ItoY, MiyachiM, KikuchiK, HosoiH and AkaoY. (2017). Cancer-specific energy metabolism in rhabdomyosarcoma cells is regulated by microRNA. Nucleic Acid Ther, 27:365–377.
9.
HeM, WangJ, YinZ, ZhaoY, HouH, FanJ, LiH, WengZ, TangJ, et al. (2019). MiR-320a induces diabetic nephropathy via inhibiting MafB. Aging (Albany NY), 11:3055–3079.
10.
FemminellaGD, FerraraN and Rengo.G (2015). The emerging role of microRNAs in Alzheimer's disease. Front Physiol, 6:40.
11.
WangY, ZhangS, BaoH, MuS, ZhangB, MaH and MaS (2018). MicroRNA-365 promotes lung carcinogenesis by downregulating the USP33/SLIT2/ROBO1 signalling pathway. Cancer Cell Int, 18:64.
12.
ZhangHB, SunLC, LingL, CongLH and LianR. (2016). miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor. Exp Ther Med, 12:1795–1802.
13.
MishraS, YadavT and RaniV. (2016). Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol, 98:12–23.
14.
LiuG and LiB. (2019). Role of miRNA in transformation from normal tissue to colorectal adenoma and cancer. J Cancer Res Ther, 15:278–285.
15.
ChiY and Zhou.D (2016). MicroRNAs in colorectal carcinoma—from pathogenesis to therapy. J Exp Clin Cancer Res, 35:43.
16.
KnudsenKN, LindebjergJ, NielsenBS, HansenTF and Sorensen.FB (2017). MicroRNA-200b is downregulated in colon cancer budding cells. PLoS One, 12:e0178564.
17.
YouC, LiangH, SunW, LiJ, LiuY, FanQ, ZhangH, YueX and Li.J (2016). Deregulation of the miR-16-KRAS axis promotes colorectal cancer. Sci Rep, 6:37459.
18.
KanaanZ, RobertsH, EichenbergerMR, BilleterA, OcheretnerG, PanJ, RaiSN, JordenJ, WillifordA and GalandiukS. (2013). A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg, 258:400–408.
19.
ZhuY, ZhaoH, RaoM and XuS. (2017). MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. Oncol Rep, 37:2185–2192.
20.
HanJG, JiangYD, ZhangCH, YangYM, PangD, SongY-N and ZhangG-Q. (2017). A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res, 92:55–66.
21.
KangSM, LeeHJ and ChoJY. (2013). MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer. Cancer Lett, 335:487–494.
22.
ZhangP, ZhengC, YeH, TengY, ZhengB, YangX and ZhangJ. (2014). MicroRNA-365 inhibits vascular smooth muscle cell proliferation through targeting cyclin D1. Int J Med Sci, 11:765–770.
23.
GuoSL, YeH, TengY, WangYL, YangG, LiXB, ZhangC, YangX, YangZZ and Yang.X (2013). Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun, 4:2544.
24.
Lea MA. (2010). Recently identified and potential targets for colon cancer treatment. Future Oncol, 6:993–1002.
25.
NieJ, LiuL, ZhengW, ChenL, WuX, XuY, DuX and HanW. (2012). microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting cyclin D1 and Bcl-2. Carcinogenesis, 33:220–225.
26.
ChivukulaRR, ShiG, AcharyaA, MillsEW, ZeitelsLR, AnandamJL, AbdelnabyAA, BalchGC, MansourJC, et al. (2014). An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell, 157:1104–1116.
27.
AkaoY, NakagawaY and NaoeT. (2006). MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep, 16:845–850.
28.
TakagiT, IioA, NakagawaY, NaoeT and TanigawaN. (2009). Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology, 77:12–21.
29.
SzczyrbaJ, LoprichE, WachS, JungV, UntereggerG, BarthS, GrobholzR, WielandW, StöhrR, et al. (2010). The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res, 8:529–538.
30.
DrebberU, LayM, WedemeyerI, VallbohmerD, BollschweilerE, BrabenderJ, MönigSP, HölscherAH, DienesHP and OdenthalM. (2011). Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol, 39:409–415.
31.
XuXH, WuXB, WuSB, LiuHB, ChenR and Li.Y (2014). Identification of miRNAs differentially expressed in clinical stages of human colorectal carcinoma-an investigation in Guangzhou, China. PLoS One, 9:e94060.
32.
TanogluA, BaltaAZ, BerberU, OzdemirY, EmirzeogluL, SayilirA and SuculluI. (2015). microRNA expression profile in patients with stage II colorectal cancer: a turkish referral center study. Asian Pac J Cancer Prev, 16:1851–1855.
33.
RoyP, DasS, AuddyRG and MukherjeeA. (2014). Engineered andrographolide nanosystems for smart recovery in hepatotoxic conditions. Int J Nanomed, 9:4723–4735.
34.
WangW, JiG, XiaoX, ChenX, QinWW, YangF, LiYF, FanLN, XiWJ, et al. (2016). Epigenetically regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1. Oncotarget, 7:68674–68687.
35.
IbrahimAF, WeirauchU, ThomasM, GrunwellerA, HartmannRK and AignerA. (2011). MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res, 71:5214–5224.
36.
LimaJF, CerqueiraL, FigueiredoC, OliveiraC and AzevedoNF. (2018). Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol, 15:338–352.
37.
DavisS, LolloB, FreierS and EsauC. (2006). Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res, 34:2294–2304.
38.
TangL, ChenHY, HaoNB, TangB, GuoH, YongX, DongH and YangSM. (2017). microRNA inhibitors: natural and artificial sequestration of microRNA. Cancer Lett, 407:139–147.
EbertMS, NeilsonJR and SharpPA. (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods, 4:721–726.
41.
LiuJ, CarmellMA, RivasFV, MarsdenCG, ThomsonJM, SongJJ, HammondSM, Joshua-TorL and HannonGJ. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305:1437–1441.
42.
EbertMS and SharpPA. (2010). MicroRNA sponges: progress and possibilities. RNA, 16:2043–2050.
43.
EbertMS and SharpPA. (2010). Emerging roles for natural microRNA sponges. Curr Biol, 20:R858–R861.
44.
ElchevaI, GoswamiS, NoubissiFK and SpiegelmanVS. (2009). CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol Cell, 35:240–246.
45.
BakRO, HollensenAK and MikkelsenJG. (2013). Managing microRNAs with vector-encoded decoy-type inhibitors. Mol Ther, 21:1478–1485.
46.
BakRO and MikkelsenJG. (2014). miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA, 5:317–333.
47.
OtaegiG, PollockA and Sun.T (2011). An optimized sponge for microRNA miR-9 affects spinal motor neuron development in vivo. Front Neurosci, 5:146.
48.
KluiverJ, GibcusJH, HettingaC, AdemaA, RichterMK, HalsemaN, Slezak-ProchazkaI, DingY, KroesenBJ and van den BergA. (2012). Rapid generation of microRNA sponges for microRNA inhibition. PLoS One, 7:e29275.
49.
KluiverJ, Slezak-ProchazkaI, Smigielska-CzepielK, HalsemaN, KroesenBJ and Van den BergA. (2012). Generation of miRNA sponge constructs. Methods, 58:113–117.
50.
BaiJ, ZhangZ, LiX and LiuH. (2015). MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. Cancer Biomark, 15:599–608.
51.
AppaiahHN, GoswamiCP, MinaLA, BadveS, SledgeGW, LiuY and Nakshatri.H (2011). Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res, 13:R86.
52.
WanJ, DengD, WangX, JiangS and CuiR. (2019). LINC00491 as a new molecular marker can promote the proliferation, migration and invasion of colon adenocarcinoma cells. Onco Targets Ther, 12:6471–6480.
53.
LiF and MahatoRI. (2015). miRNAs as targets for cancer treatment: therapeutics design and delivery. Preface. Adv Drug Deliv Rev, 81:v–vi.
54.
ChenL, ZhangK, ShiZ, ZhangA, JiaZ, WangG, PuP, KangC and HanL. (2014). A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncol Rep, 31:1573–1580.
55.
LiY, KuscuC, BanachA, ZhangQ, Pulkoski-GrossA, KimD, LiuJ, RothE, LiE, et al. (2015). miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res, 75:2674–2685.
56.
WangXW, HeXJ, LeeKC, HuangC, HuJB, ZhouR, XiangXY, FengB and LuZQ. (2016). MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts. Int J Cardiol, 208:79–86.
57.
ShenB, YuanY, ZhangY, YuS, PengW, HuangX and FengJ. (2017). Long non-coding RNA FBXL19-AS1 plays oncogenic role in colorectal cancer by sponging miR-203. Biochem Biophys Res Commun, 488:67–73.
58.
XuJ, ZhangR and ZhaoJ. (2017). The novel long noncoding RNA TUSC7 inhibits proliferation by sponging MiR-211 in colorectal cancer. Cell Physiol Biochem, 41:635–644.
59.
BernardoBC, GregorevicP, RitchieRH and McMullen.JR (2018). Generation of microRNA-34 sponges and tough decoys for the heart: developments and challenges. Front Pharmacol, 9:1090.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
